These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 20017932

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Banting Memorial Lecture 2016 Reducing lifetime risk of complications in adolescents with Type 1 diabetes.
    Dunger DB.
    Diabet Med; 2017 Apr; 34(4):460-466. PubMed ID: 27973749
    [Abstract] [Full Text] [Related]

  • 6. Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments.
    Marcovecchio ML, Woodside J, Jones T, Daneman D, Neil A, Prevost T, Dalton RN, Deanfield J, Dunger DB, AdDIT Investigators.
    Diabetes Care; 2014 Apr; 37(3):805-13. PubMed ID: 24198300
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
    Undas A, Brummel-Ziedins KE, Potaczek DP, Stobierska-Dzierzek B, Bryniarski L, Szczeklik A, Mann KG.
    J Thromb Haemost; 2006 Nov; 4(11):2397-404. PubMed ID: 16907931
    [Abstract] [Full Text] [Related]

  • 10. The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction.
    Bank AJ, Kelly AS, Kaiser DR, Crawford WW, Waxman B, Schow DA, Billups KL.
    Vasc Med; 2006 Nov; 11(4):251-7. PubMed ID: 17390549
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.
    Fassett RG, Ball MJ, Robertson IK, Geraghty DP, Coombes JS.
    BMC Nephrol; 2008 Mar 18; 9():4. PubMed ID: 18366658
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.
    Am J Cardiovasc Drugs; 2010 Mar 18; 10(2):73-84. PubMed ID: 20136164
    [Abstract] [Full Text] [Related]

  • 18. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators.
    Wanner C, Krane V, Ruf G, März W, Ritz E.
    Kidney Int Suppl; 1999 Jul 18; 71():S222-6. PubMed ID: 10412782
    [Abstract] [Full Text] [Related]

  • 19. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators.
    Lancet; 1999 Jul 18; 364(9435):685-96. PubMed ID: 15325833
    [Abstract] [Full Text] [Related]

  • 20. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS).
    Zhang J, Shao Y, Liu Y, Tao J.
    Cardiovasc Drugs Ther; 2018 Dec 18; 32(6):581-589. PubMed ID: 30187345
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.